 |
|
Effectiveness of Statin Therapy in Adults With Coronary Heart Disease
Timothy J. Wilt, MD, MPH;
Hanna E. Bloomfield, MD, MPH;
Roderick MacDonald, MS;
David Nelson, PhD;
Indulis Rutks, BS;
Michael Ho, MD;
Gregory Larsen, MD;
Anthony McCall, MD, PhD;
Sandra Pineros, MPH;
Anne Sales, PhD
Arch Intern Med. 2004;164:1427-1436.
Background We conducted a meta-analysis of patients with coronary heart disease (CHD) to determine the effectiveness of statin therapy; whether effectiveness varied according to patient characteristics, outcomes, or pretreatment low-density lipoprotein cholesterol (LDL-C) levels; and the optimal LDL-C goal and the level at which to initiate statin therapy.
Methods Randomized trials or systematic reviews for secondary prevention of CHD with statin therapy published between January 1966 and December 2002 were identified through MEDLINE and the Cochrane Library. Studies were included if they randomly assigned adults with CHD to statin therapy or control, enrolled at least 100 individuals per arm, reported clinical outcomes and LDL-C levels, and were published as full studies in English. Two reviewers abstracted data using a prospectively designed protocol.
Results Twenty-five studies enrolling 69 511 individuals were included. Participants in 19 placebo-controlled trials had a mean age of 63 years and a mean pretreatment LDL-C level of 149 mg/dL (3.85 mmol/L); 23% were women. Statin therapy reduced CHD mortality or nonfatal myocardial infarction 25% (relative risk [RR], 0.75; 95% confidence interval [CI], 0.71-0.79), all-cause mortality 16% (RR, 0.84; 95% CI, 0.79-0.89), and CHD mortality 23% (RR, 0.77; 95% CI, 0.71-0.83). Beneficial effects were seen in women and the elderly. There were no data to determine whether lowering the LDL-C level to less than 100 mg/dL (<2.59 mmol/L) was superior to lowering it to 100 to 130 mg/dL (2.59-3.36 mmol/L). Meta-regression analyses revealed risk reductions for CHD mortality or nonfatal myocardial infarction and major vascular events across available pretreatment LDL-C levels.
Conclusion Statin therapy reduces mortality and morbidity in adults with CHD, even at pretreatment LDL-C levels as low as 100 mg/dL (2.59 mmol/L).
From the Center for Chronic Disease Outcomes Research, Minneapolis VA Medical Center, Minneapolis, Minn (Drs Wilt, Bloomfield, and Nelson and Messrs MacDonald and Rutks); Cardiology and Health Services Research, Denver VA Medical Center, Denver, Colo (Dr Ho); Department of Cardiology, Portland VA Medical Center, Portland, Ore (Dr Larsen); Department of Internal Medicine, University of Virginia Health System, Charlottesville (Dr McCall); and Ischemic Heart Disease Quality Enhancement Research Initiative, VA Puget Sound Health Care System, Seattle, Wash (Ms Pineros and Dr Sales). The authors have no relevant financial interest in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Activation of Liver X Receptors Prevents Statin-induced Death of 3T3-L1 Preadipocytes
Madsen et al.
J. Biol. Chem. 2008;283:22723-22736.
ABSTRACT
| FULL TEXT
Exercise and cardiovascular risk reduction: Time to update the rationale for exercise?
Green et al.
J. Appl. Physiol. 2008;105:766-768.
FULL TEXT
Effect of Pretreatment With Statins on Ischemic Stroke Outcomes
Reeves et al.
Stroke 2008;39:1779-1785.
ABSTRACT
| FULL TEXT
Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis.
Afilalo et al.
J Am Coll Cardiol 2008;51:37-45.
ABSTRACT
| FULL TEXT
Sex differences in the effectiveness of statins after myocardial infarction
Karp et al.
CMAJ 2007;176:333-338.
ABSTRACT
| FULL TEXT
The Value Of Coronary Heart Disease Care For The Elderly: 1987-2002
Rosen et al.
Health Aff (Millwood) 2007;26:111-123.
ABSTRACT
| FULL TEXT
Primary Prevention of Cardiovascular Diseases With Statin Therapy: A Meta-analysis of Randomized Controlled Trials
Thavendiranathan et al.
Arch Intern Med 2006;166:2307-2313.
ABSTRACT
| FULL TEXT
Statin therapy and risks for death and hospitalization in chronic heart failure.
Go et al.
JAMA 2006;296:2105-2111.
ABSTRACT
| FULL TEXT
Healthy Lifestyle Factors in the Primary Prevention of Coronary Heart Disease Among Men: Benefits Among Users and Nonusers of Lipid-Lowering and Antihypertensive Medications
Chiuve et al.
Circulation 2006;114:160-167.
ABSTRACT
| FULL TEXT
Cholesteryl Ester Transfer Protein Inhibition: Effect on Reverse Cholesterol Transport?
Rensen and Havekes
Arterioscler. Thromb. Vasc. Bio. 2006;26:681-684.
FULL TEXT
Role of cAMP Response Element Binding Protein in Cardiovascular Remodeling: Good, Bad, or Both?
Ichiki
Arterioscler. Thromb. Vasc. Bio. 2006;26:449-455.
ABSTRACT
| FULL TEXT
Statin and beta-blocker therapy and the initial presentation of coronary heart disease.
Go et al.
ANN INTERN MED 2006;144:229-238.
ABSTRACT
| FULL TEXT
Lipid Testing and Lipid-Lowering Therapy in Hospitalized Ischemic Stroke and Transient Ischemic Attack Patients: Results From a Statewide Stroke Registry
Mullard et al.
Stroke 2006;37:44-49.
ABSTRACT
| FULL TEXT
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?: A Meta-Regression Analysis
Robinson et al.
J Am Coll Cardiol 2005;46:1855-1862.
ABSTRACT
| FULL TEXT
Update in Endocrinology
Wartofsky
ANN INTERN MED 2005;143:673-682.
FULL TEXT
Identification of the Four Conventional Cardiovascular Disease Risk Factors by Dutch General Practitioners
van Wyk et al.
Chest 2005;128:2521-2527.
ABSTRACT
| FULL TEXT
Other articles noted
Evid. Based Med. 2005;10:31-32.
FULL TEXT
|
